Product Quantum (Rs. Cr) Long Term Rating Short Term Rating
Bank Loan Ratings 9.09 ACUITE C | Downgraded | Issuer not co-operating* -
Total Outstanding 9.09 - -
 
Rating Rationale

­Acuité has downgraded the long-term rating to ‘ACUITE C’ (read as ACUITE C) from ‘ACUITE BB-' (read as ACUITE double B minus)  on the Rs.9.09 crore bank facilities of Sai Tech Medicare Private Limited (STMPL). The rating continues to be flagged as “Issuer Not Cooperating” and is based on best available information.
The downgrade is based on CRIF Highmark Report which shows ongoing delays.

About the Company
­­Sai Tech Medicare Private Limited (STMPL) is a Haryana based company incorporated in the year 2008 by Mr. V.D Gupta and Mr. Jagbir Singh. The company is engaged in the manufacturing of allopathic medicines in various forms such as soft gelatine, tablets, tubes, drops, liquid syrup, ointment and injectable etc.
 
About the Group
­­Symbiosis Pharmaceuticals Private Limited was incorporated in the year 2003 by Mr. V.D Gupta and Mr. Jagbir Singh. The group is involved in the manufacturing of allopathic medicines in various forms like Soft gelatine, tablets, tubes, drops, Liquid Syrup, Ointment and Injectable etc. The group is situated at Kala Amb, Himanchal Pradesh.
 
Unsupported Rating
­Not Applicable
 
Non-cooperation by the issuer/borrower:
­­Acuité has been requesting for data, information and undertakings from the rated entity for conducting surveillance & review of the rating. However, the issuer/borrower failed to submit such information before the due date. Acuité believes that information risk is a critical component in such ratings, and non-cooperation by the issuer along with unwillingness to provide information could be a sign of potential deterioration in its overall credit quality. This rating is, therefore, being flagged as “Issuer not-cooperating”, in line with prevailing SEBI regulations and Acuité’s policies.
 
Limitation regarding information availability:
­­The rating is based on information available from sources other than the issuer/borrower (in the absence of information provided by the issuer/borrower). Acuité endeavored to gather information about the entity/industry from the public domain. Therefore, Acuité cautions lenders and investors regarding the use of such information, on which the indicative credit rating is based.
 
Rating Sensitivity
­­"No information provided by the issuer / available for Acuite to comment upon."
 
Liquidity Position
­­"No information provided by the issuer / available for Acuite to comment upon."
 
Outlook: Not Applicable
­
 
Other Factors affecting Rating
­None
 

Particulars Unit FY 22 (Actual) FY 21 (Actual)
Operating Income Rs. Cr. 260.74 215.28
PAT Rs. Cr. 3.35 3.10
PAT Margin (%) 1.28 1.44
Total Debt/Tangible Net Worth Times 1.06 0.97
PBDIT/Interest Times 2.43 2.43
Status of non-cooperation with previous CRA
­Not Applicable
 
Any other information
­None
 
Applicable Criteria
• Manufacturing Entities: https://www.acuite.in/view-rating-criteria-59.htm
• Default Recognition: https://www.acuite.in/view-rating-criteria-52.htm
• Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm

Note on Complexity Levels of the Rated Instrument
­­In order to inform the investors about complexity of instruments, Acuité has categorized such instruments in three levels: Simple, Complex and Highly Complex. Acuite’ s categorisation of the instruments across the three categories is based on factors like variability of the returns to the investors, uncertainty in cash flow patterns, number of counterparties and general understanding of the instrument by the market. It has to be understood that complexity is different from credit risk and even an instrument categorized as 'Simple' can carry high levels of risk. For more details, please refer Rating Criteria “Complexity Level Of Financial Instruments” on www.acuite.in
 

Date Name of Instruments/Facilities Term Amount (Rs. Cr) Rating/Outlook
26 Jun 2023 Cash Credit Long Term 7.00 ACUITE BB- (Reaffirmed & Issuer not co-operating*)
Proposed Long Term Loan Long Term 2.09 ACUITE BB- (Reaffirmed & Issuer not co-operating*)
13 Apr 2022 Cash Credit Long Term 7.00 ACUITE BB- (Downgraded & Issuer not co-operating* from ACUITE BB)
Proposed Long Term Loan Long Term 2.09 ACUITE BB- (Downgraded & Issuer not co-operating* from ACUITE BB)
06 Jan 2021 Cash Credit Long Term 7.00 ACUITE BB (Downgraded & Issuer not co-operating* from ACUITE BB+)
Proposed Long Term Loan Long Term 2.09 ACUITE BB (Downgraded & Issuer not co-operating* from ACUITE BB+)
­

Lender’s Name ISIN Facilities Date Of Issuance Coupon Rate Maturity Date Quantum
(Rs. Cr.)
Complexity Level Rating
State Bank of India Not avl. / Not appl. Cash Credit Not avl. / Not appl. Not avl. / Not appl. Not avl. / Not appl. 7.00 Simple ACUITE C | Downgraded | Issuer not co-operating* ( from ACUITE BB- )
Not Applicable Not avl. / Not appl. Proposed Long Term Loan Not avl. / Not appl. Not avl. / Not appl. Not avl. / Not appl. 2.09 Simple ACUITE C | Downgraded | Issuer not co-operating* ( from ACUITE BB- )
*Annexure 2 - List of Entities (applicable for Consolidation or Parent / Group / Govt. Support)
Sr.No. Company Name
1 Sai Tech Medicare Private Limited
2 Symbiosis Pharmaceuticals Private Limited
 

Contacts




About Acuité Ratings & Research

© Acuité Ratings & Research Limited. All Rights Reserved.www.acuite.in